Hitachi Chemical Co. America, Ltd. (San Jose, California), a subsidiary of Hitachi Chemical (Tokyo) has completed its purchase of the 80.1% remaining membership interest in PCT Cell Therapy Services (PCT, New Jersey) from Caladrius Biosciences.
Following the acquisition, PCT has become an independent business unit dedicated to cell therapy and regenerative medicine within the life sciences division of Hitachi Chemical.
Hitachi Chemical will leverage PCT’s extensive experience in cell therapy development and manufacturing technology, wide-ranging manufacturing locations, sales network and other resources to expand and strengthen services in the United States and add services in Japan, Europe, and other regions. In addition, PCT will be able to expand manufacturing capacity, capabilities, and service offerings.
“The acquisition of PCT marks an important milestone in the expansion of Hitachi Chemical’s regenerative medicine-related businesses,” says Hisashi Maruyama, CEO, Hitachi Chemical.
By Kartik Kohli
Source: Chemical Week
Saudi Industrial Investment Group (SIIG; Riyadh) and National Petrochemical Co. (Petrochem; Jubail, Saudi Arabia) say they have started talks over a potential merger of the two companies. SIIG and Petrochem […]
Solvay has launched its Peroxides for the Future (P4F) program, a multi-year plan to adapt its peroxides industrial footprint in EMEA and make product available where customers need it most. […]
INEOS Styrolution and Trinseo, global leaders in the manufacturing of polystyrene and other styrenic materials, announced today that they are advancing plans to build the first-of-its-kind polystyrene recycling plant based […]
